Today: 30 April 2026
Browse Category

NYSE:KVUE 14 October 2025 - 4 November 2025

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
4 November 2025
···
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark shares plunged 14.6% on Nov. 3 to a 52-week low near $102 after announcing a $40 billion cash-and-stock deal to acquire Kenvue at a 46% premium. The drop erased about 15% of KMB’s market value, with the stock now down 21% year-over-year. Investors cited concerns over Kenvue’s litigation risks and debt load. KMB trades at 17.3× earnings, with a 4.9% dividend yield.
4 November 2025
··
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kimberly-Clark announced a $48.7 billion cash-and-stock deal to acquire Kenvue, sending Kenvue shares up about 20% in pre-market trading to near $17.50. Kenvue shareholders will receive $3.50 in cash and 0.14625 KMB shares per KVUE share. Kenvue reported Q3 net profit of $398 million, beating earnings expectations. Kimberly-Clark shares fell roughly 12.5% on the news.
3 November 2025
····
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue shares plunged 13% Thursday to a record low near $14 after news of U.K. lawsuits over Johnson’s Baby Powder, representing 3,000 claimants and potential £1 billion in damages. The stock is down about 34% year-to-date and nearly 40% below its IPO price. Wall Street cut price targets and Moody’s downgraded its outlook to “negative.” Kenvue’s market cap now stands at roughly $30–31 billion.
17 October 2025
···
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue shares hit a 52-week low of $15.46 on Oct. 16, 2025, down about 5% in one day and over 27% in the past year. The company faces new UK talcum-powder lawsuits and ongoing FDA scrutiny over Tylenol, while Q2 revenue fell 4% to $3.84 billion. Moody’s affirmed its A1 rating but cut the outlook to negative. Kenvue replaced its CEO in July and launched a strategic review, considering asset sales.
16 October 2025
·
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Johnson & Johnson will spin off its $9.2 billion orthopedics business as DePuy Synthes within 18–24 months, its second major split since 2023. J&J beat Q3 2025 earnings estimates, raised its full-year revenue outlook to up to $93.9 billion, and saw shares rise 2% on Oct. 14. The move shifts J&J’s focus to higher-growth drug and device segments. CFO Joe Wolk said orthopedics innovation was “in better hands somewhere else.”
14 October 2025
·
1 2 3

Stock Market Today

  • JPMorgan Active Value ETF (JAVA) Sees $314M Inflow, Key Holdings Mixed
    April 30, 2026, 11:12 AM EDT. The JPMorgan Active Value ETF (JAVA) experienced a notable $314.1 million inflow, marking a 5% increase in outstanding units week-over-week. JAVA currently trades near its 52-week high, last at $75.68 compared to a low of $61.46. Key underlying stocks showed mixed action: NXP Semiconductors (NXPI) slipped about 2%, while Charles Schwab (SCHW) and Walt Disney (DIS) rose 0.7% and 1% respectively. ETF unit creations indicate buying of underlying assets, influencing the prices of portfolio holdings. Monitoring these flows provides insight into investor demand and market momentum within ETFs.

Latest article

Mastercard Earnings Beat Wall Street, But April Cross-Border Slowdown Hits Stock

Mastercard Earnings Beat Wall Street, But April Cross-Border Slowdown Hits Stock

30 April 2026
Mastercard shares fell 2.7% Thursday despite first-quarter profit and revenue beating estimates, as investors reacted to slower April cross-border spending growth. Adjusted earnings reached $4.60 per share on $8.4 billion revenue. Cross-border volume growth dropped to 9% in April from 13% in Q1, with travel-linked growth at just 2%. Operating expenses rose 13%, including a $202 million restructuring charge.
Why Viavi Solutions Stock Is Surging After a Big Earnings Beat

Why Viavi Solutions Stock Is Surging After a Big Earnings Beat

30 April 2026
Viavi Solutions shares surged about 20% in early U.S. trading after fiscal third-quarter revenue rose 42.8% to $406.8 million, beating estimates. Adjusted earnings reached 27 cents per share, above forecasts. The company projected fourth-quarter revenue of $427 million to $437 million. GAAP profit declined from a year earlier and cash flow was negative for the quarter.
Go toTop